Abbott tightens adjusted earnings range for Abbott Laboratories stock

Published on 10/23/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter sales rose 14.5 percent to USD 13.01 billion on October 21, 2026. Abbott Laboratories stock costs EUR 90.97 versus EUR 90.72 Xetra close.

Guidance and diagnostics shape outlook

Abbott reported USD 13.013 billion in third-quarter sales on October 21, 2026.
Full-year adjusted earnings guidance narrowed to USD 5.50-5.55 on October 21, 2026.
Abbott Laboratories stock trades at EUR 90.97 at 10:38 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.28 percent above the Xetra close of October 22, 2026.
Robert W. Baird raised its target from USD 121.00 to USD 123.00 on October 22, 2026.

SW-Reportage Blutlabor Mikroskop Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 schwarzweiße Reportage klinisches Blutbild-Labor Laborantin am Mikroskop dramatische Hochkontrast-Fotografie, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) tightened its full-year adjusted earnings guidance to USD 5.50-5.55 after reporting third-quarter results on October 21, 2026. According to Abbott, sales grew 14.5 percent to USD 13.013 billion, while adjusted diluted earnings per share rose 9.2 percent to USD 1.42.

Diagnostics lead third-quarter growth

The headline result was broad rather than uniform. Diagnostics sales reached USD 3.305 billion in the third quarter of 2026, up 46.7 percent on a reported basis and 6.4 percent on a comparable basis. Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis, giving the portfolio a second quantified growth engine.

Abbott's GAAP net earnings fell to USD 920 million from USD 1.644 billion in the third quarter of 2025. The company attributed the difference to specified items including USD 841 million of intangible amortization and approximately USD 670 million related to legal agreements, so adjusted earnings provide the cleaner comparison for the guidance range. The official release also reported first-nine-month sales of USD 36.770 billion, up 11.9 percent from USD 32.869 billion in the comparable period.

What does the earnings range signal?

The narrower USD 5.50-5.55 adjusted earnings range keeps the midpoint intact while reducing the width from USD 5.45-5.60. The company also projected fourth-quarter adjusted earnings per share of USD 1.62-1.67. For investors, the central tension is visible in the split between 14.5 percent reported sales growth and the lower full-year sales-growth outlook cited in MarketBeat as a medical-device concern.

Three dated company milestones

On March 23, 2026, Abbott completed the acquisition of Exact Sciences, a transaction reflected in USD 706 million of acquisition-related Diagnostics sales during the first nine months of 2026. On September 17, 2026, the board declared a quarterly dividend of USD 0.63 per share. On October 21, 2026, Abbott published third-quarter sales of USD 13.013 billion and the tightened guidance range, according to Abbott.

Next dated shareholder event

The declared dividend is scheduled for payment on November 16, 2026, to shareholders of record at the close of business on October 15, 2026. A separate analyst signal arrived on October 22, 2026, when Robert W. Baird raised its price target from USD 121.00 to USD 123.00 and maintained an outperform rating, as MarketBeat reported.

The euro quote versus Xetra

The modest daily spread leaves the operating update as the stronger signal for the European investor. Abbott Laboratories stock was trading at EUR 90.97 at Lang & Schwarz on October 23, 2026 at 10:38 a.m. CEST, plus 0.28 percent versus the Xetra close of October 22, 2026 (EUR 90.72). The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.